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ABSTRACT  The platelet-derived  growth factor  (PDGF)  is the  principal  mitogen  in serum  for 
cultured  cells  of mesenchymal  origin.  PDGF also  is a potent chemotactic  protein for inflam- 
matory  cells  and  for  cells  required  for  wound  repair.  Because  activity  levels  of  PDGF  in 
biological  fluids  are difficult  to  measure,  we attempted  to develop  a radioimmunoassay  for 
PDGF. Rabbits were immunized with purified PDGF; the antiserum obtained was monospecific 
for PDGF in immunodiffusion analysis against concentrated platelet lysates, serum, and plasma. 
A  radioimmunoassay  for  PDGF was developed  with  a sensitivity  of  =0.2  ng/ml.  Levels of 
PDGF in  plasma/serum  were measured  and  compared  with  PDGF  levels  determined  by a 
receptor-competition  assay and  by a  standard  biological  assay measuring  incorporation  of 
[3H]thymidine  into 3T3 cells.  Radioimmunoassay  showed apparent PDGF levels  of 50 ng/ml 
in human  plasma  and  103 ng/ml  in serum. The 50 ng/ml  PDGF  in  plasma  was unexpected 
because the plasma samples  contained little or no platelet release products as determined  by 
very low levels  of platelet factor 4. We therefore sought an  immunologically  reactive  PDGF 
molecule  in human  plasma.  No immunologically  reactive  protein was detected  by immuno- 
diffusion  analysis  or when  plasma  was treated  with an  immunoaffinity  gel.  Subsequently,  a 
1251-PDGF-binding protein was identified; the 1251-PDGF-plasma-binding  protein complex was 
not reactive with anti-PDGF immunoglobulin.  Correction for 1251-PDGF bound by the plasma- 
binding protein established serum levels of PDGF of ---50 ng/ml; ~'50 ng/ml PDGF was found 
in serum by radioreceptor-competition  assays and  by mitogenic assays as well. The plasma- 
binding protein  may serve  to clear PDGF released  in the circulation,  thereby  limiting  PDGF 
activity to its local  interactions at the site of blood-vessel  injury. 
The platelet-derived growth factor (PDGF) ~ is a potent poly- 
peptide growth factor released when  platelets are activated 
during blood coagulation and at the site of  blood-vessel injury. 
PDGF is strongly mitogenic for smooth  muscle cells,  skin 
fibroblasts, 3T3  cells,  and  cultured glial cells (1-9).  PDGF 
recently was shown to have a  second important biological 
activity in being a strong chemoattractant in vitro for human 
monocytes, neutrophils, fibroblasts, and for smooth muscles 
cells (10-13). While the precise roles of PDGF in vivo remain 
to be defined, these combined biological properties of PDGF 
as a  potent mitogen and chemoattractant suggest a  unique 
role for PDGF in inflammation and in wound healing. These 
properties also make PDGF an ideal agent to mediate several 
I Abbreviations  used  in  this  paper:  PDGF,  platelet-derived growth 
factor;, DME medium,  Dulbecco's modified Eagle's medium; PBS, 
phosphate-buffered saline; PF4, platelet factor 4. 
of the  initial  events in  the  pathological process of human 
atherosclerosis. 
We have recently purified PDGF to homogeneity (14-16) 
and used the purified protein to immunize rabbits. The anti- 
serum  has  been  used  to  develop a  radioimmunoassay for 
PDGF in biological fluids,  and the results of radioimmunoas- 
say have been compared with those obtained from a  newly 
developed receptor competition assay and with the mitogenic 
assay of PDGF in vitro. 
During the course of these experiments a plasma protein 
was discovered which bound ~25I-PDGF and which interfered 
with the radioimmunoassay developed to measure PDGF in 
plasma/serum. 
MATERIALS  AND  METHODS 
Materials:  Swiss  mouse 3T3 fibroblasts (CLL 92) were obtained from 
the American Type Culture Collection (Rockville, MD). Dulbecco's modified 
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cluster  plates  (24  wells, 16-mm well diameter)  were obtained  from Costar 
(Cambridge,  MA). Nat25I (17  Ci/mg)  and  [methyl-3H]thymidine  (79.4  Ci/ 
mmol) were purchased from New England Nuclear (Boston, MA). Protein A- 
sepharose CL-4B (lot EM 15161) was obtained from Pharmacia Fine Chemical 
(Piscataway, NJ). Human serum albumin (25%) was obtained  from American 
Red Cross. Bio-Gel P-6 (50-100  mesh), Bio-Gel A 1.5 m (100-200  mesh), and 
DEAE-blue gel were obtained  from Bio-Rad  Laboratories  (Richmond,  CA). 
Glutaraldehyde (25%) was obtained from Sigma Chemical Co. (St. Louis, MO). 
lmmunodiffusion plates were obtained  from Hyland  Diagnostics (Deerfield, 
IL). IgGsorb was obtained from the Enzyme Center, Inc. (Boston, MA). Keyhole 
limpet hemocyanin  was the kind gift of Dr. Joseph Davie, (Washington Uni- 
versity School of Medicine). 
PDGF:  PDGF was purified from human platelet-rich plasma as described 
previously and was separated into two homogeneous,  equally mitogenic pro- 
teins, PDGF I and PDGF 11 (14-16).  The homogeneity of individual prepara- 
tions of PDGF I and PDGF I1 was established by analytical SDS PAGE and 
by isoelectric focusing (15). The specific activity of PDGF II was ---6 x  105 U/ 
my.  PDGF  was  measured  by  use  of the  Bio-Rad  protein  assay  (Bio-Rad 
Laboratories).  The assay was correlated  with the true protein  concentration 
after measurements of dry weight and by the method of Lowry. 
Iodination  of PDGF:  PDGF II was radiolabeled with Na~2SI as pre- 
viously described and was stored in 0.1 M acetic acid containing human serum 
albumin ( 1 mg/ml)  at -20"C (17). Radiolabeled PDGF II retained full biological 
activity as measured in a standard  [3H]thymidine incorporation  assay (15, 16). 
Nearly 0.7 mol of iodide was incorporated  per mole of PDGF with a specific 
radioactivity of 16 t~Ci/#g t25I-PDGF. 
Coupling of PDGF to Keyhold Limpet Hemocyanin:  5 mg 
of  keyhole limpet hemocyanin was dissolved in 0.45 ml of 0. ! M NaHCO3 (pH 
9.0) and reacted with 0.05 ml of 2.5% glutaraldehyde. After 2 h at 22"C, free 
glutaraldehyde was removed by Bio-Gel P-6 (50-100 mesh, 0.9 x  30 cm) gel 
permeation.  2  mg  of glutaraldehyde-treated hemocyanin  was subsequently 
reacted with 212/@ of PDGF I] at room temperature for 18 h, dialyzed against 
0.1 M  acetic acid, and lyophilized. After coupling =10% of the weight of the 
conjugate was estimated to be PDGF. 1.5 mg of PDGF/hemocyanin conjugate 
dissolved in 0.25 ml  of 0.1  M  NaHCO3 (pH 9.0) was mixed with  an equal 
volume of complete Freund's adjuvant and injected into the footpads of a 2-kg 
male New Zealand rabbit. At three subsequent 3-wk intervals, 20 #g of PDGF 
in complete Freund's adjuvant  was also given. Blood for analysis was obtained 
from the central ear artery  1 d before each injection, and serum was removed 
after 2 h of allowing the blood to clot. 
Purification of Anti-PDGF:  The immune serum was partially puri- 
fied with a DEAE blue gel column (18). Endogenous PDGF in rabbit serum 
was retained on the column, whereas rabbit IgG appeared in the fiow-through 
fractions. 
Immunodiffusion:  lmmunodiffusion plates (Hyland Diagnostic) were 
incubated overnight at room temperature in a moist chamber. For staining 
with Coomassie Brilliant Blue, the immunodiffusion plates were kept in 0.9% 
NaCI to remove nonimmunoprecipitable substances, fixed in 25% isopropyl 
alcohol-10% acetic acid, and stained for t/2 h with 0.25% Coomassie Brilliant 
Blue in 50% methanol. The immunodiffusion plates were then destained with 
multiple changes of 10% isopropyl alcohol-10%  acetic acid. 
Concentration  of Human  Platelet  Lysates:  Human platelets 
obtained  from  1 U  of blood  were suspended  in 2 ml of PBS solution  and 
frozen-thawed twice, concentrated  to 0.1  ml in dialysis tubing with dextmn 
powder, and, after centrifugation, the supernate was tested in immunodiffusion 
analysis. 
Human Plasma and Serum:  12 samples  of human plasma were 
kindly provided  by Dr.  Shirley Levine, (University of Texas Health  Science 
Center,  San Antonio),  with  PF4  levels ranging  from  14  ng/ml to 52  ng/ml 
(average of 37 +  15 ng/ml). Other plasma samples were prepared according to 
procedures  as previously  described  by  Dr.  Levine  (19). Human sere  were 
obtained from normal healthy volunteers according to standard procedures of 
the clinical laboratory.  The serum and plasma samples were stored at -20"C 
before assay. 
Radioimmunoassay  Procedure:  The  reaction  mixture  (0.2 ml) 
contained  10 tA of antiserum (1:150 dilution),  10  ~1 of the  test  sample  or 
standard PDGF (0-20 ng) in 10 mM sodium phosphate buffer (pH 7.4), 0.1% 
Tween 80, 0.5 M NaCI, 0.01% sodium azide, and 0.5% human serum albumin. 
After 19 h at 22"C, 5 ng of 12~I-PDGF in 0.1 ml of the above phosphate buffer 
was added. After 2 h at 22"C, 50 #1 of 10% IgGsorb was added, the incubation 
was continued  for another 2 h, and the mixture was centrifuged. The immu- 
noprecipitate  was washed  three  times with  the  above  phosphate  buffer and 
radioactivity  measured  with  a  Beckman  gamma counter (Beckman  Instru- 
ments, Inc., Pale Alto, CA). An internal  standard  of PDGF (0.2 ng) was also 
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included  in the test samples. Nonspecific binding  was measured  with a  100 
molar excess unlabeled PDGF and with nonimmune serum substituted for the 
anti-PDGF antisera. 
Receptor-Competition Assay:  The assay conditions  were essen- 
tially identical to those previously described in binding  assays for L251-PDGF 
(17).  1 ml of the assay medium consisted of 5 ng mI-PDGF, test samples or 
standard  PDGF,  0  to  20  ng/ml, and  5%  plasma-derived  serum in  5  mM 
HEPES, 0.15 M NaCI (pH 7.4) buffer solution. Two concentrations  of serum/ 
plasma (10 ul, 20 ui) with or without 2 og of PDGF (internal  standard) were 
assayed. All assays were carried out in duplicate. 
Mitogenic Activity Assay:  The mitogenic  activity  of PDGF was 
measured by assaying the PDGF-dependent  incorporation  of [3H-methyl]thy- 
midine into a trichloroacetie acid precipitate  after incubation  with confluent 
Swiss mouse 3T3 fibroblasts in MEM and 1% plasma-derived serum (16). The 
dose  responses of assays were carried  out within  the linear  raoge of added 
PDGF (0-20 og); epidermal growth factor and fibroblast growth factor (0-100 
ng/ml) do not elicit a linear dose response curve under the conditions  of our 
assay system. Sera and plasma (5, 10, and 20 ul) were measured in the presence 
and  absence  of 2  ng of PDGF (internal  standard).  Under standard  assay 
conditions,  a  linear dose response was found with either  standard  PDGF or 
sera; nondetectable PDGHike mitogenic activity was present in plasma. 
Bio-Gel A-1.5 m  Gel Permeation Chromatography:  200 ~l 
of human plasma or 10 mM sodium phosphate buffer, pH 7.4, 0.15 M NaCI 
containing  100 ng of t25I-PDGF was applied to a column of Bio-Gel A-I.5 m 
(0.9 x  52 cm) previously equilibrated with 10 mM sodium phosphate (pH 7.4) 
containing  0.15 M NaCI, 0.01% sodium azide, and human serum albumin (1 
mg/ml) and eluted with the same buffer. Fractions of  0.7 ml were collected and 
counted for radioactivity. 
SDS Gel Electrophoresis and Autoradiography:  5 and  15% 
PAGE were carried out according to the procedure described by Laemmli (20). 
Gels  were  stained  with  Coomassie  Brilliant  Blue, destained  with  10%  2- 
propanol/10%  acetic  acid, and  dried  on  filter  paper (Bio-Rad  filter  paper 
backing). Radiolabeled  proteins were visualized by exposure of the dried gels 
to Kodak  XAR-5 films with DuPont lightning-plus intensifying screens (Du- 
Pont Instruments, Wilmington, DE). 
RESULTS 
The specificity of rabbit anti-human PDGF antisera was tested 
by immunodiffusion analysis. PDGF II and a highly concen- 
trated platelet lysate (see Materials and Methods) were tested 
against anti-human PDGF  antisera (Fig.  I a).  A  single  im- 
munoprecipitin line is observed between antisera and each 
antigen;  the  precipitin  lines  are  smoothly  fused  between 
PDGF  and platelet lysates.  The absence of spur formation 
between immunoprecipitin lines and the absence of  additional 
immunoprecipitin lines suggest that the antiserum recognizes 
purified PDGF and only PDGF in lysates of human platelets. 
When PDGF  I and PDGF  II are tested against each other, 
immunological identity of the two proteins was found (Fig. 
1 b). Immunocross-reactive protein was not found in plasma 
samples tested (data not shown). The immunological identity 
of PDGF  I  and PDGF  II is consistent with the identity of 
these  proteins  in  direct  binding  analyses  (17)  and  in  the 
mitogenic responsiveness of Swiss mouse 3T3  cells to each 
protein (16). 
A  quantitative assessment of the potency of the antisera 
was next made using sequential dilution (Fig.  2).  With  ~:5I- 
PDGF at 5  ng/ml,  50%  precipitation of 125I-PDGF was ob- 
served at a  dilution of antisera of  1:5,000;  8%  of the  ~25I- 
PDGF was precipitated at a  1:40,000 dilution. 
The  antiserum  was then  tested  to  see  whether it  would 
block the binding of t25I-PDGF to Swiss mouse 3T3 cells and 
the PDGF-dependent  mitogenic response of 3T3  cells (Fig. 
3). Increasing concentrations of antiserum effectively blocked 
the binding of ~25I-PDGF to Swiss mouse 3T3 cells. Complete 
inhibition  of ~2sI-PDGF  binding to  3T3  cells was observed 
when 500 ~g of antiserum was added to the binding assay. As 
the concentration of antiserum is reduced, the inhibition of FIGURE  1  (a) Immunodiffusion of human PDGF II, 
human  PDGF  I and  human  platelet lysates against 
rabbit anti-PDGF antiserum. The concentrations of 
PDGF  II and PDGF  I were 0.5 mg/ml. The platelet 
lysates were added at a concentration of 1 U  plate- 
lets/0.1 ml PBS. The center well contains antiserum. 
The immunodiffusion plates were stained with Coo- 
massie Brilliant Blue. (b) Immunodiffusion of human 
PDGF  II  and  human  PDGF  I  against  rabbit  anti- 
PDGF  II antiserum. The concentrations of PDGF  I 
and PDGF II were 0.5 mg/ml in H20. 
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FIGURE  2  Anti-PDGF  serum  dilution  curve.  The  assay  medium 
contained 5 ng of ~2sI-PDGF (10,000 cpm/ng) and  10 #1 of various 
dilutions of anti-PDGF antiserum in 0.3 ml of RIA assay buffer. The 
immunoprecipitation with IgGsorb was carried out as described in 
Materials and Methods. The radioactivity precipitated with nondi- 
luted antiserum was taken as 100%. 
~25I-PDGF binding is progressively reduced.  The antiserum 
also effectively inhibits in parallel the PDGF-dependent stim- 
ulation  of [3H]thymidine incorporation into  DNA of Swiss 
mouse 3T3 cells. 
Samples of PDGF were then measured using the radioim- 
munoassay developed (Fig. 4). Direct measurement of PDGF 
over concentrations from 0.2 to 2 ng/ml was readily obtained. 
Repetitive  experiments  provided  identical  results;  when 
known samples were tested as unknowns, accurate estimates 
of PDGF  concentrations  were  reproducibly  obtained.  The 
radioimmunoassay was then used to measure PDGF levels in 
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FIGURE  3  Effect  of  anti-PDGF  antiserum  on  the  binding  of  1251- 
PDGF  to  3T3  fibroblasts  and  on  the  PDGF-dependent  [3H- 
methyl]thymidine incorporation into DNA of 3T3 fibroblasts. Assays 
were performed at 30 ng/ml of 12sI-PDGF and PDGF, respectively. 
PDGF  or  12sI-PDGF  was  preincubated  with  antiserum  at  room 
temperature  for  2  h  before  assay.  The  binding  and  mitogenic 
activities in the absence of antisera were taken as 100%. 
12 samples of human plasma; 55.0 +  11  ng/ml PDGF was 
found (Table I). Eight samples of human serum were meas- 
ured; PDGF levels were found to be  103  +  16  ng/ml.  The 
high levels of plasma PDGF found (---55 ng/ml) raised the 
possibility  that  PDGF  was  released  from  platelets  during 
preparation of plasma. Both PF4 and PDGF activities have 
been localized to a-granules in platelets (6-9, 2 l, 22); radioim- 
munoassay of PF4  in  plasma samples provides a  sensitive 
index of platelet release during plasma preparation (19).  PF4 
levels were measured and found to be from 14 ng/ml to 52 
ng/ml in the plasma samples (courtesy of Dr. Shirley Levine, 
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PF4 is present at =5 pg/ml in human serum (19, 21, 22). The 
plasma samples used to estimate PDGF levels thus contained 
<1% the PF4 released in serum, providing direct evidence 
that significant release of platelet a-granule constituents did 
not occur during the collection/preparation of plasma. 
A receptor-competition assay in which PDGF is measured 
by its capacity to compete with  12~I-PDGF binding to the 
PDGF receptor on the surface of Swiss mouse 3T3 cells was 
then used to assess the high plasma levels of PDGF found by 
radioimmunoassay (Fig.  5).  PDGF levels  measured by ra- 
dioimmunoassay were  compared with  levels  measured  by 
receptor-competition (Table I).  PDGF levels were substan- 
tially <10 ng/ml in human plasma; =50 ng/ml PDGF was 
found in human serum when PDGF is measured by receptor 
competition. Due to the limitations in the sensitivity of the 
receptor competition assay at PDGF levels < 10 ng/ml, the 
levels of plasma PDGF present could not be accurately deter- 
mined even when plasma concentrations were raised to 20%. 
Plasma  and  serum  samples  were assayed  by the  standard 
mitogenic  assay.  Human  serum  contained  =--64 ng/ml  of 
PDGF; no mitogenic activity was found in human plasma 
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FIGURE  5  Standard curve of 12sI-PDGF receptor-competition  assay 
with mouse Swiss 3T3 fibroblasts. The assay medium (1  ml) con- 
sisted of 5 ng of 12sI-PDGF (1 x  104 cpm/ng) and various amounts 
of authentic  PDGF  (0-20  ng)  in  5  mM  HEPES buffer,  pH  7.4, 
containing 5% plasma-derived sera. The assay samples were tested 
in duplicate. Each point represents the mean + SE of measurements 
obtained from four different experiments. 
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FIGURE 4  Standard  curve  of the  radioimmunoassay with  rabbit 
anti-PDGF  serum.  The  procedure for  radioimmunoassay is  de- 
scribed in Materials and Methods. The samples were assayed in 
quadruplicates. Each point represents  the mean +  SE of measure- 
ments obtained from five different experiments. 
TABLE  I 
Measurement of PDGF in Human Plasma and Serum by Using 
Radioimmunoassay, Receptor-Competition Assay, and 
Mitogenic Assay 
RIA  RCA  Mitogenic assay 
ng/ml  ng/ml  ng/ml 
Human  serum*  103 _  16  50 ___ 9.0  64 ___ 4 
Human  plasma*  55 _  1  <10'  0 s 
RIA, radioimmunoassay. RCA, receptor-competition assay. 
* Each value represents the mean _+ SE of results obtained from eight human 
serum samples or 12 human plasma samples. Three levels of human serum 
and  plasma (2.5  times dilution, 5,  10, and  20 pl) were assayed +0.2  ng 
PDGE as internal standard in radioimmunoassays, and two levels of human 
serum and  plasma (10 and  20 pl) were assayed __.2 ng purified PDGF (as 
internal standard) in receptor-competition assays. 
* Levels of PDGF  in plasma samples <10 ng/ml were difficult to quantitate 
because high amounts of plasma decrease the nonspecific binding and the 
quantitation of specific 12sI-PDGF binding is less accurate. At concentrations 
of 10-20% plasma, because of decreased nonspecific binding in the assay 
an apparent value of PDGF in plasma is seen. The dose response to PDGF, 
however, is not linear. 
IA small mitogenic activity was found in human plasma. However, no dose 
response of mitogenic activity of PDGF  in increasing concentrations was 
observed. 
(Table I); these levels are consistent with those found using 
the receptor-competition assay. 
The levels of PDGF in plasma/serum found by radioim- 
munoassay were thus higher than levels found in the mito- 
genic and receptor competition assays. Subtraction of plasma 
value from the serum values obtained by radioimmunoassay 
resulted in a corrected serum level of =50 ng PDGF/ml, a 
value now consistent with serum PDGF levels obtained by 
both the mitogenic and receptor-competition assays. 
To account for the  high  levels  of PDGF in  plasma,  an 
immunologically cross-reactive protein or a protein interfer- 
ing with the  radioimmunoassay was then  sought.  2  ml  of 
plasma was pretreated with IgGSorb to remove endogenous 
human IgG. The plasma was  then incubated with 20 pl of 
specific anti-PDGF antiserum (or 20 pl of nonimmune rabbit 
serum,  as control). After incubation overnight at 4"C,  the 
plasma solution was mixed with 50 vl of 35% (wt/vol) protein 
A-agarose gel suspension, stirred for 3 h and washed sequen- 
tially with 1 ml of phosphate-buffered saline (PBS), with 1 ml 
of 0.1% Tween 80 in PBS and 0.5 M NaCI, and with 1 ml of 
PBS  solution.  The  protein  A-sepharose  gel  was  then  sus- 
pended in 200 pl of 0.3 M sodium phosphate buffer (pH 7.5) 
and  iodinated with  0.5  mCi/5  nmol Na~25I in  a  test tube 
coated with 40 vg of iodogen at room temperature for 1 h 
(17). The iodinated protein A-sepharose gel was washed with 
PBS solution, suspended in  1% SDS,  and subjected to SDS 
PAGE (7.5% and 15% acrylamide gels). No difference in the 
125I patterns  in  the  autoradiograms  were  found  between 
plasma samples treated with immune serum and nonimmune 
serum. 
The failure to demonstrate immunocross-reactive material 
in human plasma in this and in other experiments (immu- 
nodiffusion  analysis)  prompted  us  to  investigate  possible 
plasma proteins which might interact with t25I-PDGF, thereby 
interfering with the RIA assay. Incubation of 125I-PDGF  with 
plasma  followed by gel  permeation  on  Bio-Gel A  1.5  m 
showed  a  distinct  t25I-labeled fraction (peak  C)  migrating 
sustantially faster than peak A or peak B; peak C is not found 
when ~2sI-PDGF is incubated without plasma (Fig. 6a). The 
two forms (peak A  and peak  B)  found in  gel  permeation 
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dence that  the  plasma  PDGF levels measured in  the  RIA 
assay are due to complexing of  the ~25I-PDGF  added for assay 
with the plasma-binding protein, leaving less  ~25I-PDGF as- 
sociated with the antibody; the presence of an immunologi- 
cally cross-reactive material could not be demonstrated. The 
tzsI-PDGF bound to this plasma protein is able to account 
fully for the  apparent  PDGF found in  human  plasma  by 
radioimmunoassay. 
FIGURE 6  (a) Gel filtration profile of 1251-PDGF incubated with or 
without human plasma on Bio-Gel A 1.5 m gel. 100 ng of 12sI-PDGF 
was incubated with 200 ~.1 of human plasma or 200 ~.1 of 10 mM 
sodium phosphate buffer,  pH  7.4, containing 0.15  M  NaCl. After 
20 min at room temperature, the reaction mixture was applied to a 
column of Bio-Gel A  1.5 m (0.9 x  52 cm)  previously equilibrated 
with  10 mM sodium phosphate buffer, pH 7.4 containing 0.15 M 
NaCl and 0.01% sodium azide and human serum albumin (1  mg/ 
ml). The frational volume was 0.7 ml and the flow rate was 20 ml/ 
h. The radioactivity for each fraction was measured with a gamma 
counter. No significant  differences in relative radioactive distribu- 
tion in peak A, B, or C were found at concentrations of 12sI-PDGF 
from 10 ng/ml to 500  ng/ml. O, +  plasma. O, -  plasma. (b) SDS 
polyacrylamide gel autoradiographs of peak A, B, and C from Bio- 
Gel A 1.5 m gel permeation chromatography of usI-PDGF treated 
with  human plasma. 20 #1 of each'fraction which contained the 
highest radioactivity  in peak A, B, and C as shown in a was subjected 
to SDS 5% PAGE. After staining with Coomassie Brilliant Blue and 
destaining with  10% 2-propano]/10% acetic acid, the gels were 
then  dried  and  exposed to  Kodak XAR-5 films  at  -70°C  with 
DuPont lightning-plus intensifying  screens. Myosin, ~-galactosidase, 
phosphorylase B, and bovine serum albumin were used as standard 
molecular weight markers. The arrow indicates the location of 12Sl- 
PDGF-plasma binding protein complex. ~251-PDGF  appeared with 
the dye front in 5% SDS polyacrylamide  gels. The molecular  weight 
of the ~251-PDGF-plasma-binding  protein complex was measured as 
310,000. The molecular weight of peaks A and B was 30,000 and 
co-migrated with unlabeled PDGF in 15% SDS polyacrylamide  gels. 
chromatography of ~25I-PDGF at neutral pH are consistently 
present; only a single peak (free PDGF) is seen on Bio-Gel P- 
100 in 1 M acetic acid (data not shown). Peak A is free PDGF 
and peak B is felt to be a noncovalent, self  associated form of 
125I-PDGF. A sample from peak C was subjected to SDS gel 
electrophoresis and compared with samples from peaks A and 
B. Autoradiograms of  these gels showed 125I.PDGF associated 
with a high molecular weight protein in peak C (Fig. 6 b). The 
molecular weight of this  ~zsI-PDGF-plasma-binding  protein 
complex was estimated as 310,000. If the assumption is made 
that this complex contains equal molar 125I-PDGF/plasma- 
binding  protein,  the  molecular  weight  of this  '25I-PDGF 
plasma-binding protein is =280,000. The ~25I-PDGF-plasma- 
binding  protein  complex is  not dissociated by boiling,  by 
treatment with SDS,  or by 1 M acetic acid. The ~25I-PDGF 
plasma-binding protein complex retained =3% apparent im- 
munoreactivity. Experiments are in progress to characterize 
this plasma-binding protein and its interactions with PDGF. 
While the identity of this protein and the nature of its inter- 
actions with PDGF are not known, the finding of the  t25I~ 
DISCUSSION 
PDGF has been difficult to purify. Small-scale purifications 
were initially achieved (23-25), and, more recently, the large- 
scale purification of PDGF has been reported (l 4-16, 26-28). 
Our laboratory (15) succeeded in separating PDGF into two 
homogeneous protein fractions (PDGF I and PDGF II) that 
were  similar  in  amino  acid  composition  but  different  in 
carbohydrate content. PDGF II was used to generate antisera; 
antiserum to PDGF II has been obtained from rabbits. Initial 
efforts to raise antisera with purified PDGF were not success- 
ful, perhaps because binding of the highly positively charged 
PDGF  (isoelectric point  [pI]  --10.2,  reference  15)  at  the 
injection site precluded delivery of adequate antigen to sites 
for processing. PDGF coupled to homocyanin subsequently 
proved to be highly immunogenic. The anti-PDGF antisera 
obtained precipitates ~25I-PDGF from solution; loss of PDGF 
mitogenic activity after reaction with antisera correlates di- 
rectly with the decrease of z25I-PDGF binding to 3T3 cells. 
Further evidence of specificity  was found in immunodiffusion 
analysis;  a single, smoothly fused immunoprecipitin line was 
obtained  when  the  antiserum  was  tested  against  purified 
PDGF and  against  concentrated whole platelet lysates.  No 
difference in  immunological reactivity was  found between 
PDGF I and II. 
Using partially purified antisera, a radioimmunoassay sen- 
sitive in measuring 0.2 ng PDGF/ml has been developed. 55 
ng/ml PDGF was measured by radioimmunoassay in human 
plasma samples in which significant platelet release had not 
occurred during preparation as indicated by very low levels 
of PF4 in  the samples; the PDGF activity in these plasma 
samples by [3H]thymidine incorporation or by PDGF specific 
receptor competition assays  was  essentially  nondetectable. 
Immunologically cross-reactive, biologically inactive proteins 
therefore were sought in human plasma. Using partially pu- 
rified antisera,  no immunocross-reactive material could be 
identified in immunodiffusion analysis or when immobilized 
antiserum was used to adsorb plasma. Binding of ~25I-PDGF 
to a plasma protein (--280,000 mol wt) was then demonstrated 
after incubating plasma and '25I-PDGF.  The binding of ~25I- 
PDGF to the plasma-binding protein appears to account for 
the apparent PDGF levels in plasma by binding '25I-PDGF 
that otherwise would bind to the antibody during radioim- 
munoassay. About  10-20%  J25I-PDGF added to samples of 
plasma or serum is bound to the PDGF-binding protein under 
conditions of assay.  By use of internal standards,  it can be 
established that the radioimmunoassay for PDGF in serum 
accurately reflects incremental increases of PDGF over and 
above PDGF bound to the binding protein.  If the plasma 
radioimmunoassayable  levels  of "PDGFIike"  material  are 
subtracted from the serum RIA levels,  =50 ng/ml PDGF is 
estimated in human serum. These levels of PDGF are con- 
sistent with levels measured in  serum  using the  mitogenic 
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says (3T3 cells). 
A radioimmunoassay for a human serum growth factor for 
BALB/c-3T3 cells has been previously reported by Antoniades 
and Scher (29); use of the radioimmunoassay demonstrated 
this serum growth factor in platelets. The molecular weight 
of this growth factor used as antigen for raising antisera was 
estimated to be  13,000 (SDS gel electrophoresis and Bio-Gel 
P-150  gel  permeation chromatography) and its pI was 9.7. 
The relationship of the PDGF antigen used in our work (Mr 
=30,000) and the antigen reported previously (29) is not clear 
although it seems most likely that the proteins share a com- 
mon origin. No plasma PDGF-binding activity was reported. 
Heldin et al. (30) also reported the development of antiserum 
against human PDGF. This antiserum inhibited the multipli- 
cation-stimulating activity  of PDGF  and  partially  but  not 
completely cross-reacted with osteosarcoma-derived growth 
factor. A radioimmunoassay was developed with a sensitivity 
to 5 ng/ml; plasma and serum PDGF levels were not reported. 
Singh et al. (3 l) used a radioreceptor assay to measure PDGF 
in serum. They report =HI5  ng/ml PDGF in normal serum 
and <l  ng/ml  PDGF  in  serum derived  from platelet-poor 
plasma. Radioimmunoassay for PDGF was not described. 
Correlation between our three assay systems suggests that 
PDGF levels of =50 ng/ml are found in serum from normal 
humans. Serum PDGF levels from individuals may be diffi- 
cult to measure, however, because of ~25I-PDGF binding to 
the 280,000  mol wt plasma protein observed in this work. 
Serum levels can be estimated, however, by doing simulta- 
neous plasma and serum "levels" and correcting measured 
serum PDGF  levels for the apparent PDGF levels found in 
plasma. 
The presence of a 280,000 mol wt ~25I-PDGF-binding  pro- 
tein in  human plasma is of major interest.  Such a  protein 
might serve to clear PDGF released locally by platelets at sites 
of injured endothelium,  thereby limiting PDGF  activity to 
that PDGF bound locally to cells and to subendothelium. The 
nature of the binding  protein and its in  vivo  function are 
presently under investigation. 
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